These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29230203)

  • 1. Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.
    Iacob SA; Iacob DG
    Front Microbiol; 2017; 8():2323. PubMed ID: 29230203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment.
    Fessel WJ; Anderson B; Follansbee SE; Winters MA; Lewis ST; Weinheimer SP; Petropoulos CJ; Shafer RW
    Antiviral Res; 2011 Dec; 92(3):484-7. PubMed ID: 22001594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibalizumab for the treatment of multidrug-resistant HIV-1 infection.
    Rizza SA; Bhatia R; Zeuli J; Temesgen Z
    Drugs Today (Barc); 2019 Jan; 55(1):25-34. PubMed ID: 30740610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection.
    Beccari MV; Mogle BT; Sidman EF; Mastro KA; Asiago-Reddy E; Kufel WD
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30885900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection.
    Blair HA
    Drugs; 2020 Feb; 80(2):189-196. PubMed ID: 31970712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
    Emu B; Fessel J; Schrader S; Kumar P; Richmond G; Win S; Weinheimer S; Marsolais C; Lewis S
    N Engl J Med; 2018 Aug; 379(7):645-654. PubMed ID: 30110589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.
    Riccardi N; Berruti M; Del Puente F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):190-197. PubMed ID: 30378502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).
    Palella FJ; Armon C; Buchacz K; Chmiel JS; Novak RM; D'Aquila RT; Brooks JT;
    J Antimicrob Chemother; 2014 Oct; 69(10):2826-34. PubMed ID: 24942257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibalizumab: The First Monoclonal Antibody for the Treatment of HIV-1 Infection.
    Chahine EB; Durham SH
    Ann Pharmacother; 2021 Feb; 55(2):230-239. PubMed ID: 32659101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibalizumab.
    Bettiker RL; Koren DE; Jacobson JM
    Curr Opin HIV AIDS; 2018 Jul; 13(4):354-358. PubMed ID: 29746266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of antiretroviral drugs as microbicides.
    Balzarini J; Schols D
    Curr HIV Res; 2012 Jan; 10(1):53-60. PubMed ID: 22264046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibalizumab: First Global Approval.
    Markham A
    Drugs; 2018 May; 78(7):781-785. PubMed ID: 29675744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
    Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H
    Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV-1-infected patients: a French nationwide study.
    Masquelier B; Costagliola D; Schmuck A; Cottalorda J; Schneider V; Izopet J; Calvez V; Descamps D; Poggi C; Brun-Vézinet F;
    J Med Virol; 2005 Aug; 76(4):441-6. PubMed ID: 15977249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced antiretroviral drug susceptibility among patients with primary HIV infection.
    Little SJ; Daar ES; D'Aquila RT; Keiser PH; Connick E; Whitcomb JM; Hellmann NS; Petropoulos CJ; Sutton L; Pitt JA; Rosenberg ES; Koup RA; Walker BD; Richman DD
    JAMA; 1999 Sep 22-29; 282(12):1142-9. PubMed ID: 10501117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection.
    Bruno CJ; Jacobson JM
    J Antimicrob Chemother; 2010 Sep; 65(9):1839-41. PubMed ID: 20639524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical manifestations and treatment outcomes in HIV-1-infected children receiving antiretroviral therapy in Karachi, Pakistan.
    Mir F; Qamar FN; Baig-Ansari N; Abro AG; Abbas SQ; Kazi MA; Rizvi A; Zaidi AK
    J Infect Dev Ctries; 2014 Apr; 8(4):519-25. PubMed ID: 24727519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.
    Mendoza Y; Castillo Mewa J; Martínez AA; Zaldívar Y; Sosa N; Arteaga G; Armién B; Bautista CT; García-Morales C; Tapia-Trejo D; Ávila-Ríos S; Reyes-Terán G; Bello G; Pascale JM
    PLoS One; 2016; 11(4):e0154317. PubMed ID: 27119150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.